MF59 adjuvant: the best insurance against influenza strain diversity.
about
Vaxjo: a web-based vaccine adjuvant database and its application for analysis of vaccine adjuvants and their uses in vaccine developmentB Cells and Functional Antibody Responses to Combat InfluenzaHypothesis driven development of new adjuvants: short peptides as immunomodulatorsUse of a polyanionic carbomer, Carbopol971P, in combination with MF59, improves antibody responses to HIV-1 envelope glycoproteinA caprine herpesvirus 1 vaccine adjuvanted with MF59™ protects against vaginal infection and interferes with the establishment of latency in goatsEstimation of the health impact and cost-effectiveness of influenza vaccination with enhanced effectiveness in CanadaFactors contributing to the immunogenicity of meningococcal conjugate vaccinesAdjuvant efficacy of mOMV against avian influenza virus infection in mice.Assessment of antigen-specific and cross-reactive antibody responses to an MF59-adjuvanted A/H5N1 prepandemic influenza vaccine in adult and elderly subjects.An update on safety and immunogenicity of vaccines containing emulsion-based adjuvants.Bringing influenza vaccines into the 21st century.Assessment of mOMV adjuvant efficacy in the pathogenic H1N1 influenza virus vaccine.Influenza vaccination in children primed with MF59-adjuvanted or non-adjuvanted seasonal influenza vaccineComparison of the long-term immunogenicity of two pandemic influenza A/H1N1 2009 vaccines, the MF59-adjuvanted and unadjuvanted vaccines, in adultsControlling the HIV/AIDS epidemic: current status and global challengesAdjuvant solution for pandemic influenza vaccine productionAltered response to A(H1N1)pnd09 vaccination in pregnant women: a single blinded randomized controlled trialA dose-ranging study in older adults to compare the safety and immunogenicity profiles of MF59®-adjuvanted and non-adjuvanted seasonal influenza vaccines following intradermal and intramuscular administration.Cross-serotype immunity induced by immunization with a conserved rhinovirus capsid proteinAging impairs murine B cell differentiation and function in primary and secondary lymphoid tissuesDistinct TLR adjuvants differentially stimulate systemic and local innate immune responses in nonhuman primates.Immunosenescence and Challenges of Vaccination against Influenza in the Aging Population.Different human vaccine adjuvants promote distinct antigen-independent immunological signatures tailored to different pathogensProtective efficacy induced by recombinant Clostridium difficile toxin fragmentsChlamydia vaccines: recent developments and the role of adjuvants in future formulations.Improving immunogenicity and effectiveness of influenza vaccine in older adults.Pattern recognition receptors: sentinels in innate immunity and targets of new vaccine adjuvants.Adjuvants for human vaccines.The gracefully aging immune system.Adjuvanted influenza vaccines.Inactivated influenza virus vaccines: the future of TIV and QIV.Overview of Vaccine Adjuvants: Introduction, History, and Current Status.A physiologically-based pharmacokinetic (PBPK) model of squalene-containing adjuvant in human vaccines.Vaccines, reverse vaccinology, and bacterial pathogenesis.Synthetic Toll-Like Receptor 4 (TLR4) and TLR7 Ligands Work Additively via MyD88 To Induce Protective Antiviral Immunity in Mice.A pilot randomized trial of adjuvanted influenza vaccine in adult allogeneic hematopoietic stem cell transplant recipients.Terpene metabolic engineering via nuclear or chloroplast genomes profoundly and globally impacts off-target pathways through metabolite signalling.Identification of Biologically Active Pyrimido[5,4-b]indoles That Prolong NF-κB Activation without Intrinsic Activity.Emulsion based vaccine adjuvants.Vaccines for the twenty-first century society.
P2860
Q21284959-6CF1869F-EF4B-4A15-9A64-D757585094CEQ26801639-1F0DD1D0-A300-4938-81E8-7E4B0DFCD639Q27023844-8DDAE774-4ABF-4353-B0B1-222D6C4FBBFBQ28730561-E7D84B0E-0E1C-4A48-894B-C373B51FE3F0Q28730610-A710E39F-C161-4117-AB23-A20C2D1DAB63Q28742771-E61AF2B1-78DA-4054-A6ED-1A681D75F847Q28828544-0A12A58F-99E5-487E-BC74-05D00FCB26BAQ30219688-60EDF9C9-A1A3-49BB-9E43-A2BB5D8B8AC2Q30223941-D0833899-4158-45B9-86B4-B9A2905CEE21Q30352329-788E3037-6EDB-45D1-8C3F-6B029B5ADAEDQ30357413-4DCECC8C-A235-452C-B023-83FD6699FDCDQ30364462-3D78AC39-D280-46AB-B688-B85BBAFBCFB5Q30375872-2F607563-0031-4398-9B65-A65116DEFBCFQ30413670-8BB7820F-90F2-4A09-9AE0-D37396463457Q30420558-3F91D4C1-104B-4A34-B8CB-EA50589E6841Q30422038-6998F36C-5FB1-4371-A9EA-2EE38D55CA36Q30430043-DDE6160B-C419-4FD1-BF0D-676081E9FE03Q33578064-F808D2BA-8309-45C3-B71E-E7A584F1626FQ35004481-4F37650C-5A9A-4A27-B41F-E5149CCC37BBQ35806803-DE7421C7-852D-44A1-B372-EEF7E0CBFF9BQ35849215-1E787BA5-24E0-48E4-B53E-A70E6EDD0214Q35874111-18286036-CBBE-4CAE-B381-ABFEC7BF80D7Q36500269-DB40EE25-823A-4834-B931-3D977DB03189Q37036112-7BA3D3FB-C2B0-4355-BDF3-2B36C285EE65Q37849913-25906099-F325-4917-8D4F-B362C5936813Q37951523-7D3E3D96-2A2D-434A-9CF2-69C96B35B922Q37981769-203C4DFF-903A-405F-BE5C-0FFF03EC53DEQ38004229-DCA6CC96-B005-4CCC-9842-957B962240BAQ38107139-884363AE-934C-4726-8B72-5CBDA25E2159Q38140045-C0EB07EE-D11B-4A98-83D2-77082F0F6EBCQ38683726-D9E76901-6A34-44DF-B367-A4CB85277E3CQ38813523-1996E69F-2829-465A-87B5-9A2755413F7CQ39373123-40BEF814-DAAB-42E5-A4DA-6E0F77016CDAQ39426398-17D7E775-ADA4-468E-B4AE-2445995E901EQ40116011-D7D807BF-A2EC-499A-9E97-3E2BCE392CABQ40306881-41981B49-0974-469A-BA77-F55292DCFC50Q41813163-BE13BB11-7DAB-4ADF-9B61-72E689890FDFQ46360938-5D98D447-CFE2-4535-8E33-1BBB11CB85E6Q47105588-B380319B-C431-48BB-AE8A-1915AF8F53FAQ51664205-1EBF3285-40AF-433F-BFA6-52A4C4B28D98
P2860
MF59 adjuvant: the best insurance against influenza strain diversity.
description
2011 nî lūn-bûn
@nan
2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
MF59 adjuvant: the best insurance against influenza strain diversity.
@ast
MF59 adjuvant: the best insurance against influenza strain diversity.
@en
type
label
MF59 adjuvant: the best insurance against influenza strain diversity.
@ast
MF59 adjuvant: the best insurance against influenza strain diversity.
@en
prefLabel
MF59 adjuvant: the best insurance against influenza strain diversity.
@ast
MF59 adjuvant: the best insurance against influenza strain diversity.
@en
P2093
P2860
P356
P1476
MF59 adjuvant: the best insurance against influenza strain diversity.
@en
P2093
Derek T O'Hagan
Ennio De Gregorio
Giuseppe Del Giudice
Theodore Tsai
P2860
P304
P356
10.1586/ERV.11.23
P577
2011-04-01T00:00:00Z